Bundibugyo still does not have the simple pharmaceutical sentence readers may expect from generic Ebola coverage, since CDC's DRC travel notice says no vaccines or specific treatments are approved to prevent or treat Bundibugyo virus disease, while early supportive care can improve the chance of survival. [1]

That follows Monday's screening-window story, which avoided cure and vaccine overclaiming, and Tuesday's source stack makes the subtype distinction the point: Bundibugyo is not a Zaire ebolavirus vaccine story unless a sponsor, trial, or agency document says so. [1] [2] [3]

CDC repeats the same no-approved-vaccine and no-specific-treatment language in its Uganda travel notice, while WHO's May 29 disease outbreak notice says no approved vaccines or specific treatments currently exist for Bundibugyo virus disease and points instead to case identification, isolation and care, contact tracing, safe burials, infection prevention, and community engagement. [2] [3]

That does not mean care is futile; it means the care is early, supportive, and operational, built around fluids, symptoms, infection control, testing, isolation, and contact work rather than a single approved product. [1] [3]

X often compresses Ebola into one vaccine argument, but the documents do not, and they ask readers to keep the subtype, the country notice, and the care pathway attached to the disease name. [1] [2] [3]

-- KENJI NAKAMURA, Tokyo